New data shows GSK-Vir drug works against all Omicron mutations

British drugmaker GSK (GSK.L) said on Tuesday its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology (VIR.O) is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.